NHS Dudley Health Economy Medicines Formulary
Home > 2 Cardiovascular system > 2.8 Anticoagulants and protamine > 2.8.2 Oral anticoagulants > Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban - NICE TAG TA275

Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban - NICE TAG TA275

1.1 Apixaban is recommended as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with 1 or more risk factors such as:

  • prior stroke or transient ischaemic attack

  • age 75 years or older

  • hypertension

  • diabetes mellitus

  • symptomatic heart failure.

1.2 The decision about whether to start treatment with apixaban should be made after an informed discussion between the clinician and the person about the risks and benefits of apixaban compared with warfarin, dabigatran etexilate and rivaroxaban. For people who are taking warfarin, the potential risks and benefits of switching to apixaban should be considered in light of their level of international normalised ratio (INR) control.

https://www.nice.org.uk/guidance/TA275

Site by Devopa
© Copyright 2019 NHS. All rights reserved.